Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vito Lorusso

Showing results (1-10 of 218) with videos related to

Pageof 22
Sort By:
La Tunisie Medicale|January 25, 2006
What news in urological cancerVito Lorusso
Biologics : Targets & Therapy|August 27, 2009
Bevacizumab in the treatment of HER2-negative breast cancerVito Lorusso
Tumori|May 7, 2002
Prostate carcinomaVito Lorusso
Therapeutics and Clinical Risk Management|June 30, 2016
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronVito Lorusso
Expert Opinion on Therapeutic Targets|February 22, 2013
Novel plant-derived target drugs: a step forward from licorice?Vito Lorusso, Ilaria Marech
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?Mariangela Ciccarese, Vito Lorusso
The Lancet. Oncology|April 4, 2012
Second-line erlotinib for non-small-cell lung cancerVito Lorusso, Saverio Cinieri
Oncology|February 5, 2010
Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?Vincenzo Emanuele Chiuri, Vito Lorusso
Future Oncology (London, England)|November 1, 2014
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomitingVito Lorusso, Meinolf Karthaus, Matti Aapro
Translational Cancer Research|February 4, 2022
Adjuvant therapy of endometrial cancer: "taxane or not taxane, this is the question"Vito Lorusso, Simona Vallarelli, Francesco Giotta
Pageof 22

Showing results (1-10 of 218) with videos related to

Sort By:
Pageof 22
La Tunisie Medicale|January 25, 2006
What news in urological cancerVito Lorusso
Biologics : Targets & Therapy|August 27, 2009
Bevacizumab in the treatment of HER2-negative breast cancerVito Lorusso
Tumori|May 7, 2002
Prostate carcinomaVito Lorusso
Therapeutics and Clinical Risk Management|June 30, 2016
Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronVito Lorusso
Expert Opinion on Therapeutic Targets|February 22, 2013
Novel plant-derived target drugs: a step forward from licorice?Vito Lorusso, Ilaria Marech
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2008
How should we prescribe lapatinib to our patients: once daily or twice daily, and at what dose?Mariangela Ciccarese, Vito Lorusso
The Lancet. Oncology|April 4, 2012
Second-line erlotinib for non-small-cell lung cancerVito Lorusso, Saverio Cinieri
Oncology|February 5, 2010
Which patients with estrogen receptor-positive early breast cancer should be treated with adjuvant chemotherapy?Vincenzo Emanuele Chiuri, Vito Lorusso
Future Oncology (London, England)|November 1, 2014
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomitingVito Lorusso, Meinolf Karthaus, Matti Aapro
Translational Cancer Research|February 4, 2022
Adjuvant therapy of endometrial cancer: "taxane or not taxane, this is the question"Vito Lorusso, Simona Vallarelli, Francesco Giotta
Pageof 22